The inhibitory effects of cisplatin‑radiation combination treatment on malignant osteosarcoma MG‑63 cells and BRCA1‑p53 pathways are more efficient than single treatments

Sun,Hong‑Bin; Wang,He‑Yuan; Wu,Bing; Wang,Zhong‑Feng; Wang,Li‑Zhe; Li,Fu‑Qiang; Wu,Jun‑Duo; Zhang,Le‑Ning

doi:10.3892/ol.2019.11019

The inhibitory effects of cisplatin‑radiation combination treatment on malignant osteosarcoma MG‑63 cells and BRCA1‑p53 pathways are more efficient than single treatments

Authors:
- Hong‑Bin Sun
- He‑Yuan Wang
- Bing Wu
- Zhong‑Feng Wang
- Li‑Zhe Wang
- Fu‑Qiang Li
- Jun‑Duo Wu
- Le‑Ning Zhang
View Affiliations

Affiliations: Department of Thoracic Surgery, China‑Japan Union Hospital of Jilin University, Changchun, Jilin 130033, P.R. China, Department of Endocrinology and Metabolism, The First Hospital of Jilin University, Changchun, Jilin 130021, P.R. China, Department of Neurosurgery, China‑Japan Union Hospital of Jilin University, Changchun, Jilin 130033, P.R. China, Department of Hepatology, The First Hospital of Jilin University, Changchun, Jilin 130021, P.R. China, Department of Pediatric Oncology, The First Hospital of Jilin University, Changchun, Jilin 130021, P.R. China, Eye Center of The Second Hospital of Jilin University, Changchun, Jilin 130041, P.R. China, Department of Cardiology, The Second Hospital of Jilin University, Changchun, Jilin 130041, P.R. China
Published online on: October 29, 2019 https://doi.org/10.3892/ol.2019.11019
Pages: 6385-6396
Copyright: © Sun et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The poor prognosis of patients with osteosarcoma remains a persistent problem, in particular for patients with unresectable tumors or metastasis. Therefore, combination of radiotherapy and chemotherapy has been considered for patients with metastasis or recurrence, patients unsuitable for surgery and patients refusing surgery. The present study aimed to investigate the effect of the combined treatment with cisplatin and radiation therapy on the biological characteristics of the osteosarcoma cell line MG‑63 and the breast cancer 1 (BRCA1)‑associated signaling pathways. Cell proliferation was determined using Cell Counting kit‑8 assay, and cell apoptosis and cell cycle were assessed by flow cytometry. Cell migration was examined by Transwell assay. The mRNA and protein expression levels of candidate genes, including BRCA1 and p53, were determined by reverse transcription‑quantitative PCR and western blotting, respectively. The results demonstrated that combined treatment with radiation and cisplatin significantly inhibited MG‑63 cell proliferation compared with radiation or cisplatin treatment alone. Furthermore, radiation, cisplatin or the combined treatment with radiation and cisplatin increased the apoptosis rate of MG‑63 cells, which resulted in G2 phase arrest, and significantly decreased the migratory capacity of MG‑63 cells. In addition, the apoptosis rate of MG‑63 cells following combined radiation and cisplatin treatment was higher compared with the cisplatin group, but lower compared with the radiation group. Furthermore, combined treatment with radiation and cisplatin decreased the mRNA and protein expression levels of BRCA1 and p53. Additionally, combined treatment with radiation and cisplatin had a more potent inhibitory effect on p53 expression than on BRCA1 expression. In addition, combination of radiation and cisplatin had a higher inhibitory effect on Bax protein level and a higher inductive effect on Bcl‑2 protein level compared with treatments with radiation and cisplatin alone. The results demonstrated that combined treatment of radiation and cisplatin exhibited superior therapeutic effects on osteosarcoma MG‑63 cells compared with radiation or cisplatin treatment alone, which may be mediated by the BRCA1‑p53 signaling pathway.

View Figures

View References

1	Mirabello L, Troisi RJ and Savage SA: International osteosarcoma incidence patterns in children and adolescents, middle ages and elderly persons. Int J Cancer. 125:229–234. 2009. View Article : Google Scholar : PubMed/NCBI
2	Mirabello L, Troisi RJ and Savage SA: Osteosarcoma incidence and survival rates from 1973 to 2004: Data from the Surveillance, Epidemiology, and End Results Program. Cancer. 115:1531–1543. 2009. View Article : Google Scholar : PubMed/NCBI
3	Yang Y, Han L, He Z, Li X, Yang S, Yang J, Zhang Y, Li D, Yang Y and Yang Z: Advances in limb salvage treatment of osteosarcoma. J Bone Oncol. 10:36–40. 2017. View Article : Google Scholar : PubMed/NCBI
4	McGuire J, Utset-Ward TJ, Reed DR and Lynch CC: Re-calculating! Navigating through the osteosarcoma treatment roadblock. Pharmacol Res. 117:54–64. 2017. View Article : Google Scholar : PubMed/NCBI
5	Luetke A, Meyers PA, Lewis I and Juergens H: Osteosarcoma treatment-where do we stand? A state of the art review. Cancer Treat Rev. 40:523–532. 2014. View Article : Google Scholar : PubMed/NCBI
6	Friebele JC, Peck J, Pan X, Abdel-Rasoul M and Mayerson JL: Osteosarcoma: A meta-analysis and review of the literature. Am J Orthop (Belle Mead NJ). 44:547–553. 2015.PubMed/NCBI
7	Bacci G and Lari S: Adjuvant and neoadjuvant chemotherapy in osteosarcoma. Chir Organi Mov. 86:253–268. 2001.PubMed/NCBI
8	Carrle D and Bielack SS: Current strategies of chemotherapy in osteosarcoma. Int Orthop. 30:445–451. 2006. View Article : Google Scholar : PubMed/NCBI
9	Ferrari S and Serra M: An update on chemotherapy for osteosarcoma. Expert Opin Pharmacother. 16:2727–2736. 2015. View Article : Google Scholar : PubMed/NCBI
10	Anninga JK, Gelderblom H, Fiocco M, Kroep JR, Taminiau AH, Hogendoorn PC and Egeler RM: Chemotherapeutic adjuvant treatment for osteosarcoma: Where do we stand? Eur J Cancer. 47:2431–2445. 2011. View Article : Google Scholar : PubMed/NCBI
11	Bacci G, Ferrari S, Longhi A, Picci P, Mercuri M, Alvegard TA, Saeter G, Donati D, Manfrini M, Lari S, et al: High dose ifosfamide in combination with high dose methotrexate, adriamycin and cisplatin in the neoadjuvant treatment of extremity osteosarcoma: Preliminary results of an Italian Sarcoma Group/Scandinavian Sarcoma Group pilot study. J Chemother. 14:198–206. 2002. View Article : Google Scholar : PubMed/NCBI
12	Bodmer N, Walters DK and Fuchs B: Pemetrexed, a multitargeted antifolate drug, demonstrates lower efficacy in comparison to methotrexate against osteosarcoma cell lines. Pediatr Blood Cancer. 50:905–908. 2008. View Article : Google Scholar : PubMed/NCBI
13	Duffaud F, Egerer G, Ferrari S, Rassam H, Boecker U and Bui-Nguyen B: A phase II trial of second-line pemetrexed in adults with advanced/metastatic osteosarcoma. Eur J Cancer. 48:564–570. 2012. View Article : Google Scholar : PubMed/NCBI
14	Machak GN, Tkachev SI, Solovyev YN, Sinyukov PA, Ivanov SM, Kochergina NV, Ryjkov AD, Tepliakov VV, Bokhian BY and Glebovskaya VV: Neoadjuvant chemotherapy and local radiotherapy for high-grade osteosarcoma of the extremities. Mayo Clin Proc. 78:147–155. 2003. View Article : Google Scholar : PubMed/NCBI
15	Chou AJ and Gorlick R: Chemotherapy resistance in osteosarcoma: Current challenges and future directions. Expert Rev Anticancer Ther. 6:1075–1085. 2006. View Article : Google Scholar : PubMed/NCBI
16	Li S, Sun W, Wang H, Zuo D, Hua Y and Cai Z: Research progress on the multidrug resistance mechanisms of osteosarcoma chemotherapy and reversal. Tumour Biol. 36:1329–1338. 2015. View Article : Google Scholar : PubMed/NCBI
17	Ozaki T, Flege S, Kevric M, Lindner N, Maas R, Delling G, Schwarz R, von Hochstetter AR, Salzer-Kuntschik M, Berdel WE, et al: Osteosarcoma of the pelvis: Experience of the Cooperative Osteosarcoma Study Group. J Clin Oncol. 21:334–341. 2003. View Article : Google Scholar : PubMed/NCBI
18	Ozaki T, Flege S, Liljenqvist U, Hillmann A, Delling G, Salzer-Kuntschik M, Jürgens H, Kotz R, Winkelmann W and Bielack SS: Osteosarcoma of the spine: Experience of the Cooperative Osteosarcoma Study Group. Cancer. 94:1069–1077. 2002. View Article : Google Scholar : PubMed/NCBI
19	Mohamad O, Imai R, Kamada T, Nitta Y and Araki N; Working Group for Bone and Soft Tissue Sarcoma, : Carbon ion radiotherapy for inoperable pediatric osteosarcoma. Oncotarget. 9:22976–22985. 2018. View Article : Google Scholar : PubMed/NCBI
20	Matsunobu A, Imai R, Kamada T, Imaizumi T, Tsuji H, Tsujii H, Shioyama Y, Honda H and Tatezaki S; Working Group for Bone and Soft Tissue Sarcomas, : Impact of carbon ion radiotherapy for unresectable osteosarcoma of the trunk. Cancer. 118:4555–4563. 2012. View Article : Google Scholar : PubMed/NCBI
21	Delaney G, Jacob S, Featherstone C and Barton M: The role of radiotherapy in cancer treatment: Estimating optimal utilization from a review of evidence-based clinical guidelines. Cancer. 104:1129–1137. 2005. View Article : Google Scholar : PubMed/NCBI
22	Schwarz R, Bruland O, Cassoni A, Schomberg P and Bielack S: The role of radiotherapy in oseosarcoma. Cancer Treat Res. 152:147–164. 2009. View Article : Google Scholar : PubMed/NCBI
23	Wu D, Chen K, Bai Y, Zhu X, Chen Z, Wang C, Zhao Y and Li M: Screening of diagnostic markers for osteosarcoma. Mol Med Rep. 10:2415–2420. 2014. View Article : Google Scholar : PubMed/NCBI
24	Engert F, Kovac M, Baumhoer D, Nathrath M and Fulda S: Osteosarcoma cells with genetic signatures of BRCAness are susceptible to the PARP inhibitor talazoparib alone or in combination with chemotherapeutics. Oncotarget. 8:48794–48806. 2017. View Article : Google Scholar : PubMed/NCBI
25	Li B and Ye Z: Epigenetic alterations in osteosarcoma: Promising targets. Mol Biol Rep. 41:3303–3315. 2014. View Article : Google Scholar : PubMed/NCBI
26	Turner N, Tutt A and Ashworth A: Hallmarks of ‘BRCAness’ in sporadic cancers. Nat Rev Cancer. 4:814–819. 2004. View Article : Google Scholar : PubMed/NCBI
27	Lord CJ and Ashworth A: BRCAness revisited. Nat Rev Cancer. 16:110–120. 2016. View Article : Google Scholar : PubMed/NCBI
28	Lee JA, Paik EK, Seo J, Kim DH, Lim JS, Yoo JY and Kim MS: Radiotherapy and gemcitabine-docetaxel chemotherapy in children and adolescents with unresectable recurrent or refractory osteosarcoma. Jpn J Clin Oncol. 46:138–143. 2016.PubMed/NCBI
29	Dinçbaş FO, Koca S, Mandel NM, Hiz M, Dervişoğlu S, Seçmezacar H, Oksüz DC, Ceylaner B and Uzel B: The role of preoperative radiotherapy in nonmetastatic high-grade osteosarcoma of the extremities for limb-sparing surgery. Int J Radiat Oncol Biol Phys. 62:820–828. 2005. View Article : Google Scholar : PubMed/NCBI
30	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
31	Marín A, Martín M, Liñán O, Alvarenga F, López M, Fernández L, Büchser D and Cerezo L: Bystander effects and radiotherapy. Rep Pract Oncol Radiother. 20:12–21. 2014. View Article : Google Scholar : PubMed/NCBI
32	Lewanski CR and Gullick WJ: Radiotherapy and cellular signalling. Lancet Oncol. 2:366–370. 2001. View Article : Google Scholar : PubMed/NCBI
33	Wang D and Lippard SJ: Cellular processing of platinum anticancer drugs. Nat Rev Drug Discov. 4:307–320. 2005. View Article : Google Scholar : PubMed/NCBI
34	Muggia F: Platinum compounds 30 years after the introduction of cisplatin: Implications for the treatment of ovarian cancer. Gynecol Oncol. 112:275–281. 2009. View Article : Google Scholar : PubMed/NCBI
35	Marcu L, van Doorn T and Olver I: Cisplatin and radiotherapy in the treatment of locally advanced head and neck cancer-a review of their cooperation. Acta Oncol. 42:315–325. 2003. View Article : Google Scholar : PubMed/NCBI
36	Petrelli F, De Stefani A, Raspagliesi F, Lorusso D and Barni S: Radiotherapy with concurrent cisplatin-based doublet or weekly cisplatin for cervical cancer: A systematic review and meta-analysis. Gynecol Oncol. 134:166–171. 2014. View Article : Google Scholar : PubMed/NCBI
37	Jacinto JK, Co J, Mejia MB and Regala EE: The evidence on effectiveness of weekly vs triweekly cisplatin concurrent with radiotherapy in locally advanced head and neck squamous cell carcinoma (HNSCC): A systematic review and meta-analysis. Br J Radiol. 90:201704422017. View Article : Google Scholar : PubMed/NCBI
38	Zhong Q, Chen CF, Li S, Chen Y, Wang CC, Xiao J, Chen PL, Sharp ZD and Lee WH: Association of BRCA1 with the hRad50-hMre11-p95 complex and the DNA damage response. Science. 285:747–750. 1999. View Article : Google Scholar : PubMed/NCBI
39	Caestecker KW and Van de Walle GR: The role of BRCA1 in DNA double-strand repair: Past and present. Exp Cell Res. 319:575–587. 2013. View Article : Google Scholar : PubMed/NCBI
40	Zhang J and Powell SN: The role of the BRCA1 tumor suppressor in DNA double-strand break repair. Mol Cancer Res. 3:531–539. 2005. View Article : Google Scholar : PubMed/NCBI
41	Song H, Cicek MS, Dicks E, Harrington P, Ramus SJ, Cunningham JM, Fridley BL, Tyrer JP, Alsop J, Jimenez-Linan M, et al: The contribution of deleterious germline mutations in BRCA1, BRCA2 and the mismatch repair genes to ovarian cancer in the population. Hum Mol Genet. 23:4703–4709. 2014. View Article : Google Scholar : PubMed/NCBI
42	Ramus SJ and Gayther SA: The contribution of BRCA1 and BRCA2 to ovarian cancer. Mol Oncol. 3:138–150. 2009. View Article : Google Scholar : PubMed/NCBI
43	Ratanaphan A: A DNA repair BRCA1 estrogen receptor and targeted therapy in breast cancer. Int J Mol Sci. 13:14898–14916. 2012. View Article : Google Scholar : PubMed/NCBI
44	Chechlinska M and Nowak R: The sensitivity of BRCA1 mutation carriers to ionising radiation: Questions of methodology. Breast Cancer Res Treat. 115:4332009. View Article : Google Scholar : PubMed/NCBI
45	Shi M, Ma F, Liu J, Xing H, Zhu H, Yu J and Yang M: A functional BRCA1 coding sequence genetic variant contributes to prognosis of triple-negative breast cancer, especially after radiotherapy. Breast Cancer Res Treat. 166:109–116. 2017. View Article : Google Scholar : PubMed/NCBI
46	Hallam S, Govindarajulu S, Huckett B and Bahl A: BRCA1/2 mutation-associated breast cancer, wide local excision and radiotherapy or unilateral mastectomy: A systematic review. Clin Oncol (R Coll Radiol). 27:527–535. 2015. View Article : Google Scholar : PubMed/NCBI
47	Flórez MM, Fêo HB, da Silva GN, Yamatogi RS, Aguiar AJ, Araújo JP Jr and Rocha NS: Cell cycle kinetics, apoptosis rates and gene expressions of MDR-1, TP53, BCL-2 and BAX in transmissible venereal tumour cells and their association with therapy response. Vet Comp Oncol. 15:793–807. 2017. View Article : Google Scholar : PubMed/NCBI
48	Zheng Q, Wang B, Gao J, Xin N, Wang W, Song X, Shao Y and Zhao C: CD155 knockdown promotes apoptosis via AKT/Bcl-2/Bax in colon cancer cells. J Cell Mol Med. 22:131–140. 2018. View Article : Google Scholar : PubMed/NCBI
49	Fokkema E, De Vries EG, Groen HJ, Meijer C and Timens W: Expression of apoptosis-related proteins and morphological changes in a rat tumor model of human small cell lung cancer prior to and after treatment with radiotherapy, carboplatin, or combined treatment. Virchows Arch. 442:349–355. 2003.PubMed/NCBI
50	Miyazaki T, Kato H, Faried A, Sohda M, Nakajima M, Fukai Y, Masuda N, Manda R, Fukuchi M, Ojima H, et al: Predictors of response to chemo-radiotherapy and radiotherapy for esophageal squamous cell carcinoma. Anticancer Res. 25:2749–2755. 2005.PubMed/NCBI
51	Jeong SH, Jung JH, Han JH, Kim JH, Choi YW, Lee HW, Kang SY, Hwang YH, Ahn MS, Choi JH, et al: Expression of Bcl-2 predicts outcome in locally advanced non-small cell lung cancer patients treated with cisplatin-based concurrent chemoradiotherapy. Lung Cancer. 68:288–294. 2010. View Article : Google Scholar : PubMed/NCBI
52	Hassan C, Afshinnekoo E, Li S, Wu S and Mason CE: Genetic and epigenetic heterogeneity and the impact on cancer relapse. Exp Hematol. 54:26–30. 2017. View Article : Google Scholar : PubMed/NCBI
53	Gentric G, Mieulet V and Mechta-Grigoriou F: Heterogeneity in cancer metabolism: New concepts in an old field. Antioxid Redox Signal. 26:462–485. 2017. View Article : Google Scholar : PubMed/NCBI
54	Dagogo-Jack I and Shaw AT: Tumour heterogeneity and resistance to cancer therapies. Nat Rev Clin Oncol. 15:81–94. 2018. View Article : Google Scholar : PubMed/NCBI